-- 英国药品和保健产品监管局（MHRA）周五宣布，葛兰素史克（GSK）的Linerixibat（商品名为Lynavoy）已获批准用于治疗成人原发性胆汁性胆管炎引起的瘙痒。 MHRA表示，这种口服疗法旨在减少与这种罕见肝病相关的胆汁酸积聚，从而缓解持续性瘙痒。 MHRA补充道，此次批准基于3期临床试验数据，数据显示Linerixibat与安慰剂相比，能显著减轻瘙痒并改善睡眠障碍。 周五，葛兰素史克股价下跌1.2%。
Price: $52.01, Change: $-0.30, Percent Change: -0.57%
IMAX (IMAX) is poised to surpass 50% earnings before interest, taxes, depreciation and amortization margins by 2028 as the company continues to benefit from an uptick in volume and quality for filmed-for-IMAX titles in 2026 through 2028, Wedbush said in a Friday note.Wedbush said IMAX remains on its "Best Ideas List" and that the company sees further upside from global footprint expansion, higher volume of alternative content to boost revenue and its global box office increasingly relying on a mix of local language and global fare.The 2026 to 2027 "global film slate underscores IMAX's growing prominence in Hollywood and worldwide as an essential partner for major theatrical releases across genres, languages, and geographies," according to the note.Wedbush reiterated its outperform rating with a $46 price target.Price: $35.35, Change: $-2.68, Percent Change: -7.04%
Western Digital (WDC) is expected to benefit further from accelerating demand for hard disk drives after a "great" fiscal Q3 results, Morgan Stanley said in a Friday report."AI training, inferencing, and agentic workflows are driving accelerating HDD demand, supporting WDC's confidencein >25% long-term nearline EB CAGR," the report said.The note said visibility is also extending, with some hyperscalers locking down capacity into 2029.The note added that its June quarter gross margin guide of 51% to 52% was optically weak, but it reflects conservatism, rather than any weak pricing or cost trends."This quarter reinforces our bullishness on HDDs as a whole, and WDC," the report said. Morgan Stanley boosted its price target to $488 from $380 while reiterating its overweight rating.Price: $427.61, Change: $-6.91, Percent Change: -1.59%
Pegasystems (PEGA) is poised to accelerate annual contract value growth and meet its 2026 free cash flow target as Blueprint, its low-code workflow-design platform, plays a larger role in early customer engagement, Wedbush Securities said Friday in a report.Wedbush said it is "incrementally more bullish" following discussions with Pegasystems executives and the recent pullback in shares appears "overblown."Blueprint is simplifying how Pegasystems works with prospective customers by helping them design and visualize use cases during initial meetings, historically a costly hurdle for the company, Wedbush said. The platform's ease of use supports expectations that new customers will drive about 15% of subscription-contract growth in fiscal 2026, up from 10% previously, the report said.On costs, Pegasystems has taken a "methodical approach" to stock-based Compensation, keeping it in the 8% to 9% range of revenue and prioritizing consistency rather than tying compensation to fluctuating stock prices, Wedbush said. That discipline should support sustainable free cash flow generation despite broader software-sector pressures, the report said.Wedbush maintained its outperform rating on Pegasystems stock with a price target of $60.Price: $36.53, Change: $-0.02, Percent Change: -0.05%